Dmitry Balyasny’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-86,106
| Closed | -$8.35M | – | 1625 |
|
|
2019
Q3 | $8.35M | Buy |
86,106
+18,431
| +27% | +$1.85M | 0.06% | 444 |
|
|
2019
Q2 | $6.93M | Buy |
67,675
+41,635
| +160% | +$4.49M | 0.04% | 508 |
|
|
2019
Q1 | $2.96M | Buy |
+26,040
| New | +$1.91M | 0.02% | 717 |
|
|
2018
Q4 | – | Sell |
-29,581
| Closed | -$1.61M | – | 1941 |
|
|
2018
Q3 | $1.61M | Buy |
29,581
+19,893
| +205% | +$1.36M | 0.01% | 1050 |
|
|
2018
Q2 | $802K | Sell |
9,688
-20,736
| -68% | -$1.6M | ﹤0.01% | 1191 |
|
|
2018
Q1 | $2.03M | Sell |
30,424
-27,756
| -48% | -$1.6M | 0.01% | 987 |
|
|
2017
Q4 | $2.99M | Sell |
58,180
-71,703
| -55% | -$5.15M | 0.01% | 1024 |
|
|
2017
Q3 | $11.6M | Buy |
129,883
+70,483
| +119% | +$5.35M | 0.05% | 457 |
|
|
2017
Q2 | $3.55M | Buy |
59,400
+30,400
| +105% | +$1.7M | 0.01% | 832 |
|
|
2017
Q1 | $1.55M | Sell |
29,000
-42,600
| -59% | -$2.53M | 0.01% | 979 |
|
|
2016
Q4 | $3.57M | Sell |
71,600
-124,300
| -63% | -$6.66M | 0.02% | 779 |
|
|
2016
Q3 | $11.8M | Buy |
195,900
+98,400
| +101% | +$5.67M | 0.07% | 359 |
|
|
2016
Q2 | $4.99M | Buy |
+97,500
| New | +$4.17M | 0.03% | 514 |
|
Dmitry Balyasny's ONCE Position: Q4 2019 in Review
Dmitry Balyasny sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 86,106 shares — an estimated $8.35M sold.
Dmitry Balyasny first reported a position in ONCE in Q2 2016 and held it in 13 quarters. The position peaked at $11.8M in Q3 2016. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Dmitry Balyasny reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Dmitry Balyasny sold 86,106 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $8.35M.
- Dmitry Balyasny first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2016 and held it in 13 quarters.
- Dmitry Balyasny's Spark Therapeutics, Inc. Common Stock position peaked at $11.8M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Balyasny Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.